Blockade of ICAM-1 and LFA-1 Early After Transplantation Prevents Acute Cellular Rejection and Fibrotic Progression in Allogeneic Murine Lung Transplantation Model
This study aimed to investigate the effect of inhibiting ICAM-1 and LFA-1 on acute cellular rejection and subsequent fibrosis. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Tanaka, K. Mineura, M. Takahashi, A. Ohsumi, D. Nakajima, H. Date Source Type: research
Longitudinal Dynamics of the NK Cell Repertoire After Lung Transplantation and Their Potential Role for Control in CMV Reactivation
Purpose: Lung transplantation (LTx) is the ultimate option for patients suffering from end stage lung diseases. In the early postoperative period, primary graft dysfunction (PGD) occurs as the main complication and at later time points, patients may develop chronic lung allograft dysfunction (CLAD) eventually leading to graft loss. In addition, CMV infections represent a clinically relevant complication, occurring primarily in high-risk groups, i.e. CMV-negative recipients of CMV-positive donor lungs (D+R-), associated with reduced survival rates. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Hitz, R. Bellm à s-Sanz, E. Chichelnitskiy, K. Beushausen, J. Keil, B. Wiegmann, G. Warnecke, W. Sommer, A. Ruhparwar, F. Ius, J. Kuehne, C. Falk Source Type: research
Macrophage and CD8 T Cell Discordance are Associated with Acute Lung Allograft Dysfunction Progression
Purpose: Acute lung allograft dysfunction (ALAD) is a clinical precursor to chronic lung allograft dysfunction (CLAD). However, the immunologic correlates of progression are unknown. We hypothesized that single cell investigation of bronchoalveolar lavage (BAL) cells at the time of ALAD would identify cells linked to progressive graft dysfunction. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Yellamilli, C. Ekstrand, J. Singer, S. Hays, L. Leard, R. Shah, A. Venado, M. Kleinhenz, J. Kukreja, J. Golden, A. Combes, J. Greenland Source Type: research
Exosomal Microrna-17-5p and Microrna-150-5p in Plasma as Diagnostic Markers of Chronic Lung Allograft Dysfunction After Lung Transplantation
Purpose: Circulating microRNAs (miRNAs) have been shown to be potential biomarkers for chronic lung allograft dysfunction (CLAD) after lung transplantation (LT). However, circulating miRNAs consist of miRNAs contained within apoptotic bodies which are released during cell death, protein- or lipid-mediated miRNAs, and exosomal miRNAs (exo-miRNAs) which are actively secreted by living cells. Although exo-miRNAs are involved in the pathogenesis of various diseases, little information has been available about the role of exo-miRNAs in the development of CLAD after LT. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Sugimoto, H. Choshi, S. Tanaka, K. Miyoshi, T. Hayashi, M. Umeda, T. Ryuko, H. Ujike, Y. Kubo, K. Hashimoto, K. Shien, K. Suzawa, H. Yamamoto, M. Okazaki, S. Toyooka Source Type: research
Outcomes in Patients with Acute Cellular Rejection Grade 1R: Is the Debate Over?
Purpose: Acute Cellular Rejection (ACR) grade 1R is usually untreated; however, recurrent 1Rs are associated with negative long-term outcomes. Donor-derived cell-free DNA (dd-cfDNA) is a biomarker for heart allograft injury and rejection. We hypothesize that ACR 1R concurrent with elevated dd-cfDNA may be indicative of clinically relevant rejection. We analyzed outcomes in an interim sub-analysis of patients with ACR 1R enrolled in the multicenter Prospera Test Evaluation in Cardiac Transplant (ProTECT) study, a registry of adult heart transplant (HTx) recipients in the US undergoing dd-cfDNA monitoring with the Prospera â...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: B. Lampert, , J. Hernandez Montfort, R. Kursel Obrien, C. Aggarwal-Gupta, A. Ravichandran, R. Rao, P.T. Campbell, D. Yaranov, S. Carey, M. Olymbios, M. Armer-Cabral, Z. Zhang, S. Hall Source Type: research
Performance of the National OCS Program (NOP) in US Heart and Lung Transplants
Purpose: NOP utilizes a national network of dedicated cardiothoracic surgical procurement and Organ Care System (OCS) ex-vivo perfusion clinical expertise. The NOP was established to: maximize the utilization of donor hearts and lungs for transplantation; overcome the logistical and infrastructural burden of distant donor organ procurement and national allocation; standardize the clinical quality of care for ex-vivo perfusion and assessment of cardiothoracic allografts by minimizing learning curves; and to optimize clinical resource utilization at transplant programs. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , F. Zafar, A. Hassanein, M. Al Salihi, S. Reddy, N. Dang, K. Ihnken, A. Kaw, S. LaFrancesca, M. Omara, L. Tsonis, Y. Huang, P. Lezberg, A. Jothidasan, L. Damme, X. Zhou, F. Gensini, S. Brann, T. Khayal Source Type: research
Rationale, Design and Patient Characteristics from The DevelopmEnt of Non-Invasive Cell-Free DNA to Supplant INvasivE Biopsy in Heart Transplantation (DEFINE-HT) Study
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive biomarker of cardiac allograft injury including cellular or antibody mediated rejection after heart transplant (HTx) with the potential to reduce the need for invasive surveillance endomyocardial biopsies. Current reports of dd-cfDNA in HTx are limited to case series or cross-sectional studies with patients enrolled at different time points post-HTx. Therefore, longitudinal data analysis among diverse patients followed from the time of transplant and during the early post-transplant period could inform more optimal use of dd-cfDNA. (Source: The Journal of He...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , K.H. Schlendorf, P.J. Kim, J.L. Kennedy, O. Wever-Pinzon, J.N. Nativi Nicolau, E. Hsich, M.M. Givertz, A.D. DeVore, K. Ghafourian, E. Kransdorf, J. Patel, M.M. Colvin, H.J. Eisen, K. Marshall, S. Carey, M. Olymbios, M.R. Mehra, J. Stehlik Source Type: research
Clinical Implications of Early vs Late Development of Donor-Specific Antibodies After Lung Transplant
Purpose: Lung transplant recipients (LTRs) can develop donor specific antibodies (DSAs), which are associated with antibody-mediated rejection (AMR). LTRs at our center undergo regular DSA surveillance in the first year post-LT, and LTRs that develop DSAs are treated, even in the absence of allograft dysfunction. These treatments are burdensome to patients and carry a significant risk of adverse effects. Thus, we sought to compare the clinical outcomes of LTRs without DSAs to those that develop DSAs early post-LT ( (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , N. Kohler, G. Bitar, B. Franz, C. Mitchell, C. Pham, K. Grief, R. Walia, S. Tokman Source Type: research
Daratumumab for Antibody Mediated Rejection in Lung Transplant
Introduction: Antibody-mediated rejection (AMR) in lung transplantation is associated with chronic lung allograft dysfunction and decreased survival. Current treatment modalities for AMR include corticosteroids, plasmapheresis, intravenous immunoglobulin (IVIG), B-cell depleting agents and proteasome inhibitors, all with variable clinical responses. Daratumumab is a monoclonal antibody that targets CD-38 on plasma cells resulting in complement-dependent cytotoxicity, antibody-dependent phagocytosis, and apoptosis. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , D. Brezhnev, L. Zaffiri, R. Rampolla Source Type: research
A Comparative Study Between Single vs Standard Two Doses of Basiliximab in Lung Transplantation
Purpose: Basiliximab (BAS) is the most commonly used induction agent in lung transplantation and has a t1/2 life of 7 days and IL-2 receptor saturation of 97% after 1 dose. As a followup, this study aims to evaluate the impact of implementing a single dose BAS protocol with the primary objective of comparing incidence of early acute cellular rejection (ACR) and chronic lung allograft dysfunction (CLAD). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Qureshi, M. Martin, H. Zerdo, K. Patel Source Type: research
The Impact of Statin Intensity on Early Progression of Cardiac Allograft Vasculopathy
Purpose: Limited research has compared relative risks and benefits of different intensity statins after heart transplant (HT). We hypothesize that higher intensity statin therapy is associated with lower rates of cardiac allograft vasculopathy (CAV) at 1-year post-HT. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Yuzefpolskaya, P.C. Colombo, D.L. Jennings Source Type: research
Rejection and Graft Vasculopathy Secondary to Effects of Crohn ’s Disease in a Heart-Transplanted Child
Introduction: Coronary allograft vasculopathy (CAV) results from a complex interplay between immune and non immune factors, with early onset CAV more likely associated with new donor specific antibodies (DSA) and evidence of rejection. Tacrolimus is absorbed both in small bowel and colon and is metabolized by CYP3a in intestinal wall and liver. Thus, inflammatory bowel disease impacting small or large bowel absorption could impact tacrolimus pharmacokinetics. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Conway, D. Freed, H. Huynh, M. Khoury, C. Kluthe, L. West, S. Urschel Source Type: research
Plasma and Bronchoalveolar Fluid Proteomes Identify Similar Pathways Associated with Allograft Dysfunction in Individual LTx Recipients with Different Underlying Conditions
Purpose: Proteomic analysis of plasma and bronchoalveolar lavage fluid (BALF) from lung transplant (LTx) recipients may identify potential biomarkers or pathways associated with allograft dysfunction. We conducted N-of-1 studies of 2 CF and 1 PH LTx recipients, and examined whether longitudinal changes in blood and BAL shed light on the molecular underpinnings of allograft dysfunction specific to CF. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , E.J. Skala, A.S. Potter, D. Hayes, A. Ziady Source Type: research
Percutaneous Coronary Intervention in Pediatric Transplant Recipients- Delaying the Inevitable
Purpose: Coronary allograft vasculopathy (CAV) is the leading cause of allograft failure in pediatric patients. Atherosclerotic coronary disease is usually focal and is managed with lifestyles modifications, medications and percutaneous interventions; however, CAV is more diffuse. Limited data is available regarding use of percutaneous interventions (PCI) for CAV. We sought to retrospectively review patients who were transplanted as pediatric patients and who underwent PCI for CAV and evaluate their outcomes. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: M.S. Purlee, , D. Lopez-Colon, M. Bleiweis, J. Jacobs, G. Peek, F. Fricker, B. Pietra, H. Vyas, J. Fudge, D. Gupta Source Type: research
The Kinetics of Donor-Derived Cell-Free DNA During Treatment of Allograft Rejection in a Highly Sensitized Heart Transplant Recipient
Introduction: Donor-derived cell-free DNA (dd-cfDNA) has been identified as a noninvasive biomarker for allograft injury in orthotopic heart transplantation (OHT) where changes in its percentage may suggest acute rejection. Its utility in following response to treatment is unclear. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: C. Aseervatham, D. Iyer, Source Type: research
